Trade Coherus BioSciences - CHRS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.45 |
| Open | 1.4 |
| 1-Year Change | -32.69% |
| Day's Range | 1.4 - 1.51 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 20, 2024 | 1.48 | 0.06 | 4.23% | 1.42 | 1.51 | 1.38 |
| Dec 19, 2024 | 1.45 | -0.13 | -8.23% | 1.58 | 1.58 | 1.43 |
| Dec 18, 2024 | 1.54 | -0.17 | -9.94% | 1.71 | 1.72 | 1.52 |
| Dec 17, 2024 | 1.69 | 0.07 | 4.32% | 1.62 | 1.72 | 1.55 |
| Dec 16, 2024 | 1.67 | 0.12 | 7.74% | 1.55 | 1.70 | 1.53 |
| Dec 13, 2024 | 1.58 | 0.10 | 6.76% | 1.48 | 1.62 | 1.48 |
| Dec 12, 2024 | 1.48 | -0.14 | -8.64% | 1.62 | 1.64 | 1.48 |
| Dec 11, 2024 | 1.62 | 0.04 | 2.53% | 1.58 | 1.65 | 1.50 |
| Dec 10, 2024 | 1.58 | -0.10 | -5.95% | 1.68 | 1.70 | 1.58 |
| Dec 9, 2024 | 1.67 | -0.09 | -5.11% | 1.76 | 1.82 | 1.65 |
| Dec 6, 2024 | 1.67 | 0.20 | 13.61% | 1.47 | 1.71 | 1.44 |
| Dec 5, 2024 | 1.48 | -0.27 | -15.43% | 1.75 | 1.75 | 1.48 |
| Dec 4, 2024 | 1.69 | -0.04 | -2.31% | 1.73 | 1.92 | 1.66 |
| Dec 3, 2024 | 1.68 | -0.37 | -18.05% | 2.05 | 2.41 | 1.65 |
| Dec 2, 2024 | 1.34 | 0.11 | 8.94% | 1.23 | 1.35 | 1.20 |
| Nov 29, 2024 | 1.20 | -0.07 | -5.51% | 1.27 | 1.28 | 1.19 |
| Nov 27, 2024 | 1.23 | -0.04 | -3.15% | 1.27 | 1.32 | 1.21 |
| Nov 26, 2024 | 1.25 | 0.05 | 4.17% | 1.20 | 1.36 | 1.17 |
| Nov 25, 2024 | 1.19 | 0.09 | 8.18% | 1.10 | 1.31 | 1.10 |
| Nov 22, 2024 | 1.08 | 0.01 | 0.93% | 1.07 | 1.12 | 1.03 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Coherus BioSciences Company profile
About Coherus Biosciences Inc
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. It operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences Co., Ltd., CIMERLI, a Lucentis biosimilar candidate in-licensed for commercial rights in the United States and Canada from Bioeq, and a bevacizumab (Avastin) biosimilar in-licensed for commercial rights in the United States from Innovent Biologics (Suzhou) Co., Ltd. It is also developing an internal immuno-oncology pipeline in preclinical and translational science, bioinformatics, analytical characterization, process science engineering, and clinical-regulatory development and commercialization.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Coherus Biosciences Inc revenues decreased 31% to $326.6M. Net loss totaled $287.1M vs. income of $132.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Research and development increase from $128.9M to $344.4M (expense), General and administrative increase of 20% to $138.1M (expense).
| Industry: | Bio Therapeutic Drugs |
C/O Dennis M. Lanfear
201 Redwood Shores Parkway, Suite 200
REDWOOD CITY
CALIFORNIA 94065
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com